ZVRA
Neutral signalScored 2026-10-18 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
Zevra Therapeutics, Inc.
- Nom
- Zevra Therapeutics, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $584.9M
- Employés
- 61
- PDG
- Neil F. McFarlane
- Site web
- https://zevra.com
- Marché
- ALKSANROGHRSJAZZMPLTNBIX
Zevra Therapeutics, Inc., founded in 2006 and based in Celebration, Florida, is a biopharmaceutical company dedicated to discovering and developing innovative treatments for rare diseases. The company employs its proprietary Ligand Activated Therapy (LAT) technology to create novel prodrug versions of existing FDA-approved medications or to enable new applications for other compounds, primarily addressing serious medical conditions within the United States. Zevra's development pipeline is strategically concentrated on high-unmet-need therapeutic areas, including attention deficit hyperactivity disorder (ADHD), stimulant use disorder, and various rare central nervous system (CNS) conditions, such as idiopathic hypersomnia (IH). Their lead product candidate, KP1077, which is a prodrug of d-methylphenidate (known as serdexmethylphenidate), is currently in Phase II clinical trials for the treatment of both IH and narcolepsy. Another key prodrug candidate, KP879, is also advancing through Phase II studies for stimulant use disorder. In addition to its pipeline, Zevra has successfully secured FDA approval for two products: AZSTARYS, a once-daily treatment for ADHD in patients aged six years and older, and APADAZ, an immediate-release combination product containing benzhydrocodone (a prodrug of hydrocodone) and acetaminophen. The company's product portfolio also includes arimoclomol, and it holds collaboration and licensing agreements with KVK-Tech, Inc. and Commave Therapeutics SA. Formerly known as KemPharm, Inc., the company officially rebranded to Zevra Therapeutics, Inc. in February 2023.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 20 000 titres (~224 948,00 $ US)
- Insiders
- McFarlane Neil F.
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$838,100
Avg sell (VWAP, 90d window) $11.18 vs last close $10.16 (-9.1%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$699,722 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-12
- Liquidity
- Thin $8,968,789/day · 20d vol
- Last synced
-
2026-10-19 21:11:06
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-12 | McFarlane Neil F. | Sell · S · 10b5-1 | 20,000 | $11.25 | $224,948 | Form 4 |
| 2026-08-14 | Thompson Rahsaan | Sell · S · 10b5-1 | 42,666 | $11.13 | $474,774 | Form 4 |
| 2026-08-10 | Watton Corey Michael | Sell · S | 12,300 | $11.25 | $138,377 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-10-18 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
ZVRA shows encouraging accounting profitability improvements in 2025, but persistent negative operating and free cash flow undermine the quality of those earnings and raise sustainability concerns.
The first sentence of the analysis written for ZVRA on 2026-10-18 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Unavailable or mixed. Current ratio 5.68 · operating margin -4.0% — readings disagree
Suggested stop 8.83, nearest stored support minus 0.5 ATR(13.1% under the last close). Reward/risk to the next stored resistance is 0.93. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-15 Zevra Therapeutics: Cash Plus A Drug Priced Below Its Rival''s Deal Zevra Therapeutics is rated Buy, with a fair value of $13.38 per share, 28.7% above current levels. ZVRA''s valuation is anchored by $260.2M in cash and a drug business priced at less than a fifth of its rival''s acquisition value. Miplyffa''s US launch is slow but stable; key risks are insurer restrictions and potential sales declines, with Europe currently valued at zero.
- 2026-10-06 Zevra Therapeutics: Miplyffa Validates The Bull Case, Europe Still The Swing Factor Zevra Therapeutics is a buy-rated, single-asset rare disease play with Miplyffa driving strong U.S. growth and early profitability. 2Q26 net revenue reached $39.7M, up 53% YoY, with Miplyffa contributing $30.2M and high patient retention supporting a durable franchise thesis. Management''s diagnosis expansion efforts suggest the NPC addressable market may be up to 900 patients, extending the growth runway beyond initial estimates.
- 2026-09-15 Zevra Therapeutics, Inc. (ZVRA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Zevra Therapeutics, Inc. (ZVRA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2026-09-02 Zevra Therapeutics to Present at Upcoming Investor Conferences BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that members of Zevra''s executive leadership team will present at the following investor conferences in New York, NY.
- 2026-08-25 Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium BOSTON, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced the presentation of two posters featuring long-term real-world data on MIPLYFFA® (arimoclomol) for the treatment of Niemann-Pick disease type C (NPC) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium. “These presentations further expand the growing body of evidence supporting the long-term safety and effectiveness of arimoclomol in NPC,” said Caroline Hastings, MD, Professor of Pediatrics, UCSF Benioff Children''s Hospital Oakland.
- 2026-08-21 Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) BOSTON, Mass., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that the Company has granted options to purchase an aggregate of 92,200 shares of the Company''s common stock (the “Inducement Awards”) to four new employees pursuant to the Company''s 2023 Employment Inducement Award Plan. Each Inducement Award vests over four years, with 25% vesting on the first anniversary of the employee''s start date, and the remainder vesting in three equal annual installments thereafter (subject to each such employee''s continued employment on each vesting date).
- 2026-08-13 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. ("Zevra" or the "Company") (NASDAQ: ZVRA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
- 2026-08-12 Dimensional Fund Advisors LP Acquires 400,336 Shares of Zevra Therapeutics, Inc. $ZVRA Dimensional Fund Advisors LP boosted its holdings in Zevra Therapeutics, Inc. (NASDAQ: ZVRA) by 259.2% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 554,802 shares of the company''s stock after buying an additional 400,336 shares during the quarter. Dimensional Fund Advisors
- 2026-08-11 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. (“Zevra” or the “Company”) (NASDAQ: ZVRA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
- 2026-08-06 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. ("Zevra" or the "Company") (NASDAQ: ZVRA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 84.5% | 68.6% | 89.3% | 97.8% | 92.8% | |
| Ebit Margin | 88.9% | -350.6% | -162.2% | -260.5% | -28.4% | |
| Ebitda Margin | 92.7% | -323.6% | -158.6% | -251.2% | -27.5% | |
| Operating Profit Margin | -4.0% | -368.5% | -180.6% | -418.9% | 27.0% | |
| Pretax Profit Margin | 81.4% | -381.8% | -167.7% | -263.8% | -29.7% | |
| Continuous Operations Profit Margin | 78.2% | -446.9% | -167.7% | -263.5% | -29.9% | |
| Net Profit Margin | 78.2% | -446.9% | -167.7% | -263.5% | -29.9% | |
| Bottom Line Profit Margin | 72.9% | -446.9% | -167.7% | -263.5% | -219.5% | |
| Current Ratio | 5.678 | 2.525 | 1.179 | 7.721 | 27.200 | |
| Quick Ratio | 5.634 | 2.468 | 0.853 | 7.721 | 27.200 | |
| Solvency Ratio | 0.671 | -0.716 | -0.408 | -0.642 | -1.425 | |
| Cash Ratio | 1.589 | 0.992 | 0.584 | 5.445 | 26.559 | |
| Price To Earnings Ratio | 6.400 | -3.658 | -5.038 | -5.885 | -4.128 | |
| Price To Earnings Growth Ratio | -0.040 | -0.049 | -0.076 | 0.093 | 0.120 | |
| Forward Price To Earnings Growth Ratio | -0.040 | -0.049 | -0.076 | 0.093 | 0.120 | |
| Price To Earnings Diluted Ratio | 6.637 | -3.658 | -5.038 | -5.885 | -4.128 | |
| Price To Earnings Diluted Growth Ratio | -0.042 | -0.049 | -0.076 | 0.093 | 0.120 | |
| Price To Book Ratio | 3.204 | 9.725 | 3.754 | 2.107 | 2.040 | |
| Price To Sales Ratio | 4.655 | 16.336 | 8.456 | 15.580 | 9.049 | |
| Price To Free Cash Flow Ratio | -203.695 | -5.537 | -6.864 | -8.416 | 25.081 | |
| Price To Operating Cash Flow Ratio | -310.131 | -5.537 | -6.925 | -8.458 | 24.836 | |
| Debt To Assets Ratio | 0.222 | 0.339 | 0.254 | 0.163 | 0.012 | |
| Debt To Equity Ratio | 0.409 | 1.520 | 0.707 | 0.250 | 0.013 | |
| Debt To Capital Ratio | 0.290 | 0.603 | 0.414 | 0.200 | 0.012 | |
| Long Term Debt To Capital Ratio | 0.286 | 0.600 | 0.076 | 0.146 | 0.000 | |
| Financial Leverage Ratio | 1.841 | 4.491 | 2.786 | 1.535 | 1.046 | |
| Working Capital Turnover Ratio | 0.903 | 0.725 | 0.584 | 0.106 | 0.513 | |
| Operating Cash Flow Ratio | -0.041 | -2.045 | -0.455 | -1.557 | 2.468 | |
| Operating Cash Flow Sales Ratio | -0.015 | -2.950 | -1.221 | -1.842 | 0.364 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.523 | 1.000 | 1.009 | 1.005 | 0.990 | |
| Debt Service Coverage Ratio | 11.942 | -12.484 | -1.111 | -5.109 | -21.069 | |
| Interest Coverage Ratio | -0.531 | -11.836 | -33.047 | -127.060 | 20.556 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | -0.890 | -4.021 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.025 | -1.155 | -0.766 | -0.997 | 6.488 | |
| Capital Expenditure Coverage Ratio | -1.914 | 0.000 | -113.294 | -201.258 | 102.343 | |
| Dividend Paid And Capex Coverage Ratio | -1.914 | 0.000 | -113.294 | -201.258 | 102.343 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 5.029 | -5.396 | -5.350 | -4.373 | -18.830 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 84.5% | ▲15.9% | ▼-2.1% |
| Ebit Margin | 88.9% | ▲439.5% | ▲231.5% |
| Ebitda Margin | 92.7% | ▲416.3% | ▲226.3% |
| Operating Profit Margin | -4.0% | ▲364.5% | ▲185.0% |
| Pretax Profit Margin | 81.4% | ▲463.2% | ▲233.7% |
| Continuous Operations Profit Margin | 78.2% | ▲525.0% | ▲244.1% |
| Net Profit Margin | 78.2% | ▲525.0% | ▲244.1% |
| Bottom Line Profit Margin | 72.9% | ▲519.7% | ▲277.8% |
| Current Ratio | 5.678 | ▲3.152 | ▼-3.183 |
| Quick Ratio | 5.633 | ▲3.166 | ▼-3.142 |
| Solvency Ratio | 0.671 | ▲1.387 | ▲1.175 |
| Cash Ratio | 1.589 | ▲0.597 | ▼-5.445 |
| Price To Earnings Ratio | 6.400 | ▲10.058 | ▲8.862 |
| Price To Earnings Growth Ratio | -0.040 | ▲0.009 | ▼-0.050 |
| Forward Price To Earnings Growth Ratio | -0.040 | ▲0.009 | ▼-0.050 |
| Price To Earnings Diluted Ratio | 6.637 | ▲10.295 | ▲9.051 |
| Price To Earnings Diluted Growth Ratio | -0.042 | ▲0.007 | ▼-0.051 |
| Price To Book Ratio | 3.204 | ▼-6.520 | ▼-0.962 |
| Price To Sales Ratio | 4.655 | ▼-11.682 | ▼-6.160 |
| Price To Free Cash Flow Ratio | -203.695 | ▼-198.158 | ▼-163.809 |
| Price To Operating Cash Flow Ratio | -310.131 | ▼-304.594 | ▼-248.888 |
| Debt To Assets Ratio | 0.222 | ▼-0.117 | ▲0.024 |
| Debt To Equity Ratio | 0.409 | ▼-1.111 | ▼-0.171 |
| Debt To Capital Ratio | 0.290 | ▼-0.313 | ▼-0.014 |
| Long Term Debt To Capital Ratio | 0.286 | ▼-0.314 | ▲0.065 |
| Financial Leverage Ratio | 1.841 | ▼-2.650 | ▼-0.499 |
| Working Capital Turnover Ratio | 0.903 | ▲0.179 | ▲0.337 |
| Operating Cash Flow Ratio | -0.041 | ▲2.004 | ▲0.285 |
| Operating Cash Flow Sales Ratio | -0.015 | ▲2.935 | ▲1.118 |
| Free Cash Flow Operating Cash Flow Ratio | 1.522 | ▲0.522 | ▲0.417 |
| Debt Service Coverage Ratio | 11.942 | ▲24.426 | ▲17.508 |
| Interest Coverage Ratio | -0.531 | ▲11.305 | ▲29.853 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▲0.982 |
| Operating Cash Flow Coverage Ratio | -0.025 | ▲1.130 | ▼-0.734 |
| Capital Expenditure Coverage Ratio | -1.914 | ▼-1.914 | ▲40.911 |
| Dividend Paid And Capex Coverage Ratio | -1.914 | ▼-1.914 | ▲40.911 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 5.029 | ▲10.425 | ▲10.813 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $495.6M | $385.7M | $232.2M | $158.3M | $259.3M | |
| Enterprise value | $496.4M | $412.2M | $232.9M | $111.6M | $148.5M | |
| EV / Sales | 4.66x | 17.46x | 8.48x | 10.98x | 5.18x | |
| EV / Op. cash flow | -310.63x | -5.92x | -6.95x | -5.96x | 14.23x | |
| EV / Free cash flow | -204.02x | -5.92x | -6.88x | -5.93x | 14.37x | |
| EV / EBITDA | 5.03x | -5.40x | -5.35x | -4.37x | -18.83x | |
| Net debt / EBITDA | 0.01x | -0.35x | -0.02x | 1.83x | 14.04x | |
| Current ratio | 5.68x | 2.52x | 1.18x | 7.72x | 27.20x | |
| Income quality | -0.02x | 0.66x | 0.73x | 0.70x | -1.22x | |
| Graham number | $10 | — | — | — | — | |
| Graham net-net | $1 | -$1 | -$0 | $1 | $4 | |
| Tax burden | 96.0% | 117.1% | 100.0% | 99.9% | 100.4% | |
| Interest burden | 91.6% | 108.9% | 103.4% | 101.3% | 104.6% | |
| Working capital | $183.7M | $52.0M | $13.2M | $80.8M | $110.8M | |
| Invested capital | $196.6M | $126.7M | $88.7M | $82.6M | $112.9M | |
| Return on assets | 29.2% | -59.2% | -26.7% | -23.2% | -6.4% | |
| Operating ROA | -1.8% | -49.7% | -34.5% | -34.3% | 10.7% | |
| Return on tangible assets | 30.4% | -101.0% | -46.8% | -23.2% | -6.4% | |
| Return on equity | 53.8% | -266.0% | -74.4% | -35.6% | -6.7% | |
| Return on invested capital | -1.7% | -60.2% | -36.2% | -39.2% | 6.0% | |
| Return on capital employed | -1.7% | -60.4% | -50.3% | -41.2% | 6.0% | |
| Earnings yield | 16.8% | -27.4% | -19.8% | -16.9% | -3.3% | |
| Free cash flow yield | -0.5% | -18.1% | -14.6% | -11.9% | 4.0% | |
| Capex / Op. cash flow | -52.3% | 0.0% | -0.9% | -0.5% | 1.0% | |
| Capex / Depreciation | 20.6% | 0.0% | 29.4% | 9.9% | 39.7% | |
| Capex / Sales | 0.8% | 0.0% | 1.1% | 0.9% | 0.4% | |
| SG&A / Sales | 72.9% | 232.4% | 127.8% | 148.0% | 30.4% | |
| R&D / Sales | 12.0% | 178.3% | 145.0% | 194.9% | 35.5% | |
| Stock comp / Sales | 11.9% | 63.1% | 21.7% | 0.0% | 8.5% | |
| Intangibles / Total assets | 3.9% | 41.4% | 42.9% | 0.0% | 0.0% | |
| Days sales outstanding | 80d | 162d | 231d | 298d | 19d | |
| Days payables outstanding | 55d | 643d | 1734d | 5937d | 91d | |
| Operating cycle | 118d | 259d | 3216d | 298d | 19d | |
| Cash conversion cycle | 63d | -384d | 1482d | -5639d | -72d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years